MARKET

SLXN

SLXN

Silexion Therapeutics Corp
NASDAQ
2.645
+0.060
+2.32%
After Hours: 2.640 -0.005 -0.19% 19:26 07/02 EDT
OPEN
2.590
PREV CLOSE
2.585
HIGH
2.740
LOW
2.590
VOLUME
31.27K
TURNOVER
--
52 WEEK HIGH
223.60
52 WEEK LOW
2.310
MARKET CAP
2.81M
P/E (TTM)
-0.0280
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at SLXN last week (0622-0626)?
Weekly Report · 6d ago
Analysts Are Bullish on Top Healthcare Stocks: Silexion Therapeutics (SLXN), Viking Therapeutics (VKTX)
TipRanks · 06/24 16:50
German BfArM Clears Silexion's Phase 2/3 Trial For SIL-204 In Pancreatic Cancer; Stock Down
NASDAQ · 06/24 11:02
12 Health Care Stocks Moving In Tuesday's After-Market Session
Benzinga · 06/23 21:05
Silexion Therapeutics Receives Approval From Germany's Federal Institute For Drugs And Medical Devices To Start Its Planned Phase 2/3 Clinical Study Of SIL204 In Participants With Locally Advanced Pancreatic Cancer
Benzinga · 06/23 12:41
Silexion wins Germany BfArM clearance to launch SIL204 Phase 2/3 pancreatic cancer trial
PUBT · 06/23 12:40
SILEXION THERAPEUTICS CORP - TO INITIATE PHASE 2/3 TRIAL OF SIL204 IN ISRAEL AND GERMANY
Reuters · 06/23 12:40
Silexion Therapeutics Receives Approval from Germany's BfArM to Initiate Phase 2/3 Clinical Trial of SIL204 in Locally Advanced Pancreatic Cancer
Barchart · 06/23 07:40
More
About SLXN
Silexion Therapeutics Corp is an Israel-based oncology-focused biotechnology company. The Company is engaged in development of treatments for unsatisfactorily treated solid tumor cancers, which have the mutated KRAS oncogene. The KRAS gene is an oncogene that is involved in regulation of cell division as a result of its ability to relay external signals to the cell nucleus. Based on its research of refractory solid tumor cancers, it is developing a platform focused on the silencing of the KRAS oncogene using ribonucleic acid (RNA)-interference therapeutics. Its lead product candidate, SIL-204B, consists of locally administered small interfering RNAs (siRNA), in an extended-release formulation, as a preferred treatment of locally advanced pancreatic cancer patients, in combination with standard-of-care chemotherapy. Its clinical-stage pipeline is focused on treatment for pancreatic cancer (PC) tumors bearing the KRAS G12D or KRAS G12V mutations where metastases have not been detected.

Webull offers Silexion Therapeutics Corp stock information, including NASDAQ: SLXN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SLXN stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading SLXN stock methods without spending real money on the virtual paper trading platform.